Relapsing-remitting multiple sclerosis - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱ 7 min read ✅ Medically reviewed
```html Relapsing‑Remitting Multiple Sclerosis – Complete Guide

Relapsing‑Remitting Multiple Sclerosis (RRMS)

Overview

Relapsing‑remitting multiple sclerosis (RRMS) is the most common disease course of multiple sclerosis (MS), accounting for about 85% of cases at onset.1 It is a chronic, immune‑mediated disorder in which the body’s immune system mistakenly attacks the protective myelin sheath surrounding nerve fibers in the central nervous system (CNS). Damage disrupts communication between the brain and the rest of the body, leading to a wide range of neurological symptoms.

  • Typical age of onset: 20–40 years old.
  • Gender distribution: Women are ~2–3 times more likely to develop RRMS than men.2
  • Prevalence: Approximately 2.8 million people worldwide have MS; of these, roughly 2.4 million have RRMS.3
  • Geography: Higher rates are seen in northern Europe, North America, and Australasia, suggesting a role for vitamin D and genetic background.

Symptoms

Symptoms reflect the location of demyelinating lesions and can vary widely between individuals and even from one relapse to the next. Below is a comprehensive list:

Motor Symptoms

  • Weakness or clumsiness: Often in one or both legs, sometimes affecting the arms.
  • Spasticity: Stiff, jerky muscle movements, especially in the legs.
  • Coordination problems (ataxia): Unsteady gait or difficulty with fine motor tasks.

Sensory Symptoms

  • Numbness or tingling (paresthesias): Typically begins in the face, limbs, or trunk.
  • Electric‑shock sensations (Lhermitte’s sign): A brief shock-like feeling when bending the neck forward.

Visual Symptoms

  • Optic neuritis: Painful eye movement and blurred vision in one eye, sometimes with color loss.
  • Double vision (diplopia): Resulting from lesions affecting eye‑movement muscles.

Cognitive & Emotional Symptoms

  • Memory problems: Difficulty recalling recent events.
  • Processing speed reduction: Slower thought and response times.
  • Depression & anxiety: Common due to both disease burden and neurochemical changes.

Fatigue

One of the most disabling symptoms; it is a chronic, overwhelming tiredness that is not relieved by rest.

Bladder & Bowel Dysfunction

  • Urgency, frequency, or incontinence.
  • Constipation.

Pain

  • Neuropathic pain: Burning or stabbing pain in the limbs.
  • Musculoskeletal pain: From spasticity or secondary joint strain.

Other Symptoms

  • Heat sensitivity (Uhthoff’s phenomenon): Worsening of symptoms with elevated body temperature.
  • Dysphagia (trouble swallowing) and speech changes in more extensive lesions.

Causes and Risk Factors

The exact trigger for RRMS remains unknown, but current research points to a combination of genetic susceptibility and environmental influences.

Genetic Factors

  • More than 200 genetic variants have been linked to MS risk, the strongest being HLA‑DRB1*15:01.4
  • Having a first‑degree relative with MS raises personal risk 20‑30-fold compared with the general population.

Environmental & Lifestyle Risk Factors

  • Vitamin D deficiency: Low sunlight exposure correlates with higher MS incidence.5
  • Epstein‑Barr virus (EBV) infection: A history of infectious mononucleosis markedly increases risk.6
  • Smoking: Current smokers have a 1.5‑2× higher risk and a higher chance of converting RRMS to progressive forms.7
  • Obesity in adolescence: Linked to earlier onset and greater disease activity.
  • Gender: Female hormonal factors may modulate immune response, contributing to higher prevalence.

Diagnosis

Diagnosing RRMS involves combining clinical evaluation, imaging, and laboratory studies to demonstrate dissemination of lesions in space and time.

Clinical Evaluation

  • Neurological examination documenting deficits.
  • Medical history focusing on prior attacks (relapses) and symptom pattern.

Magnetic Resonance Imaging (MRI)

Brain and spinal‑cord MRI with gadolinium contrast is the gold standard. Typical findings include:

  • Hyperintense T2 lesions in periventricular, juxtacortical, infratentorial, and spinal cord regions.
  • Enhancing lesions indicating active inflammation.

Lumbar Puncture (CSF Analysis)

  • Presence of oligoclonal bands (OCBs) not found in serum supports an immune‑mediated process.
  • Elevated IgG index.

Evoked Potentials

Visual, somatosensory, or brainstem evoked potentials can detect subclinical demyelination.

Diagnostic Criteria

The 2017 McDonald criteria integrate MRI and CSF findings to confirm dissemination in space and time, allowing earlier diagnosis.8

Treatment Options

Therapeutic goals are to reduce relapse frequency, delay disability progression, and manage symptoms.

Disease‑Modifying Therapies (DMTs)

These agents target the immune system to curb new inflammatory lesions.

Drug ClassExamplesRouteKey Points
Injectable interferons Interferon‑beta‑1a (Avonex, Rebif), Interferon‑beta‑1b (Betaseron) Subcutaneous or intramuscular injection Reduce relapse rate by ~30%; flu‑like side effects.
Glatiramer acetate Copaxone, Glatopa Subcutaneous injection Fewer systemic side effects; injection site reactions common.
Oral sphingosine‑1‑phosphate (S1P) modulators Fingolimod (Gilenya), Siponimod (Mayzent), Ozanimod (Zeposia) Oral Highly effective; monitor heart rate, liver enzymes, and lymphocyte count.
Oral dimethyl fumarate Tecfidera Oral Convenient; gastrointestinal upset, flushing, lymphopenia possible.
Oral cladribine Mavenclad Oral (short‑course) Potent efficacy; monitor blood counts.
IV monoclonal antibodies Natalizumab (Tysabri), Ocrelizumab (Ocrevus), Alemtuzumab (Lemtrada) Intravenous infusion Very high efficacy; risk of infections (e.g., PML with natalizumab).

Relapse Management

  • Corticosteroids: High‑dose IV methylprednisolone (e.g., 1 g/day for 3–5 days) speeds recovery.
  • Plasma exchange (PLEX): Considered for severe relapses unresponsive to steroids.

Symptom‑Specific Treatments

  • Spasticity – baclofen, tizanidine, or intrathecal baclofen pumps.
  • Fatigue – amantadine, modafinil, structured energy‑conservation strategies.
  • Pain – gabapentin, duloxetine, or topical agents.
  • Bladder – anticholinergics, pelvic floor therapy, intermittent catheterization if needed.

Lifestyle & Adjunctive Measures

  • Regular moderate‑intensity aerobic exercise (e.g., walking, swimming) improves mobility and mood.
  • Vitamin D supplementation (800–2,000 IU/day) if levels are low, per NIH guidelines.9
  • Smoking cessation and weight management to reduce disease activity.
  • Stress‑reduction techniques such as mindfulness, yoga, or CBT.

Living with Relapsing‑Remitting Multiple Sclerosis

RRMS is a lifelong condition, but many people lead active, fulfilling lives. Below are practical day‑to‑day strategies.

Medication Adherence

  • Set reminders (phone alarms, pillboxes).
  • Schedule regular follow‑ups to monitor efficacy and side effects.

Energy Management (Pacing)

  1. Break tasks into smaller steps.
  2. Prioritize “high‑energy” activities for times of day when you feel strongest.
  3. Incorporate rest periods (5–10 minutes) after each 30–45 minutes of activity.

Physical Therapy & Exercise

  • Core‑strengthening and balance exercises reduce fall risk.
  • Aquatic therapy can lessen joint stress while improving stamina.

Occupational Therapy

Assistive devices (e.g., reachers, shower chairs) and ergonomic modifications support independence.

Cognitive Support

  • Use memory aids: calendars, to‑do lists, smartphone apps.
  • Consider cognitive rehabilitation programs if memory or attention becomes problematic.

Psychosocial Well‑Being

  • Join MS support groups (in‑person or online) for shared experiences.
  • Seek counseling if you experience depression or anxiety; many neurologists can refer to mental‑health professionals.

Travel & Work Considerations

  • Carry medication and a letter from your neurologist outlining your condition and required treatments.
  • Advocate for reasonable workplace accommodations (flexible hours, telework, ergonomic workstation).

Prevention

Because the exact cause of RRMS is unknown, primary prevention focuses on modifying known risk factors:

  • Maintain adequate vitamin D levels: Aim for serum 25‑OH vitamin D ≄ 30 ng/mL.
  • Avoid smoking: Seek cessation programs; nicotine replacement therapy can help.
  • Limit EBV exposure in early childhood is not feasible, but early identification of infectious mononucleosis and supportive care may reduce severe infection outcomes.
  • Healthy body weight: Regular physical activity and balanced diet during adolescence lower future MS risk.
  • Vaccinations: Keep up to date (influenza, COVID‑19, HPV) to reduce infections that could trigger immune activation.

Complications

If RRMS is left untreated or inadequately controlled, several complications may arise:

  • Progression to secondary‑progressive MS: Approximately 30‑40% of RRMS patients transition within 10–20 years.
  • Permanent disability: Accumulated lesions can cause sustained weakness, gait instability, or need for wheelchair use.
  • Cognitive decline: Long‑term memory and executive function impairment.
  • Urinary tract infections (UTIs): Resulting from bladder dysfunction.
  • Depression & suicidal ideation: Higher prevalence in MS; requires proactive screening.
  • Secondary complications of treatment: For example, progressive multifocal leukoencephalopathy (PML) with natalizumab or lymphopenia with dimethyl fumarate.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

  • Sudden, severe weakness that progresses rapidly (e.g., difficulty walking, speaking, or moving an arm/leg) – possible acute‑onset relapse or spinal cord involvement.
  • New or worsening vision loss, especially if accompanied by eye pain.
  • Severe, uncontrolled bladder retention leading to inability to urinate.
  • High fever, stiff neck, or confusion – signs of infection or meningitis.
  • Significant respiratory distress or choking – rare but can occur with brainstem lesions.
  • Sudden severe headache or loss of consciousness – consider intracranial hemorrhage or other emergency.
  • Allergic reaction to medication (e.g., swelling of the face, throat, difficulty breathing).

Prompt medical attention can reduce permanent damage and improve outcomes.

References

  1. Wallin MT, et al. The prevalence of MS in the United States: A population‑based estimate using health claims data. Neurology. 2020;95(7):e1011‑e1021.
  2. Alroughani R, et al. Gender differences in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419871406.
  3. World Health Organization. Global estimates of multiple sclerosis prevalence. 2023.
  4. International Multiple Sclerosis Genetics Consortium. The genetics of multiple sclerosis. Nat Rev Neurol. 2022;18:135‑149.
  5. Munger KL, et al. Vitamin D deficiency and risk of multiple sclerosis. JAMA Neurol. 2021;78(5):600‑607.
  6. Thompson CP, et al. Epstein‑Barr virus and multiple sclerosis: A systematic review. Lancet Neurol. 2022;21(3):218‑229.
  7. Hedström AK, et al. Smoking and risk of multiple sclerosis progression. Ann Neurol. 2020;88(3):384‑395.
  8. Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162‑173.
  9. National Institutes of Health Office of Dietary Supplements. Vitamin D Fact Sheet for Health Professionals. Updated 2023.
```

⚠ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References